| Literature DB >> 33495264 |
Sakib Burza1, Yoel Lubell2,3, Arjun Chandna4,2, Endashaw M Aderie1, Riris Ahmad5, Eggi Arguni5, Elizabeth A Ashley2,6, Tanya Cope3, Vu Quoc Dat7, Nicholas P J Day2,3, Arjen M Dondorp2,3, Victor Illanes1, Joanne De Jesus8, Carolina Jimenez1, Kevin Kain9, Keang Suy10,11, Constantinos Koshiaris12, Estrella Lasry1, Mayfong Mayxay6,13, Dinesh Mondal14, Rafael Perera12, Tiengkham Pongvongsa6,15, Sayaphet Rattanavong6, Michael Rekart1, Melissa Richard-Greenblatt16, Mohammad Shomik14, Phouthalavanh Souvannasing17, Veronica Tallo8, Claudia Turner2,11, Paul Turner10,2, Naomi Waithira3, James A Watson3, Mikhael Yosia1.
Abstract
INTRODUCTION: In rural and difficult-to-access settings, early and accurate recognition of febrile children at risk of progressing to serious illness could contribute to improved patient outcomes and better resource allocation. This study aims to develop a prognostic clinical prediction tool to assist community healthcare providers identify febrile children who might benefit from referral or admission for facility-based medical care. METHODS AND ANALYSIS: This prospective observational study will recruit at least 4900 paediatric inpatients and outpatients under the age of 5 years presenting with an acute febrile illness to seven hospitals in six countries across Asia. A venous blood sample and nasopharyngeal swab is collected from each participant and detailed clinical data recorded at presentation, and each day for the first 48 hours of admission for inpatients. Multianalyte assays are performed at reference laboratories to measure a panel of host biomarkers, as well as targeted aetiological investigations for common bacterial and viral pathogens. Clinical outcome is ascertained on day 2 and day 28.Presenting syndromes, clinical outcomes and aetiology of acute febrile illness will be described and compared across sites. Following the latest guidance in prediction model building, a prognostic clinical prediction model, combining simple clinical features and measurements of host biomarkers, will be derived and geographically externally validated. The performance of the model will be evaluated in specific presenting clinical syndromes and fever aetiologies. ETHICS AND DISSEMINATION: The study has received approval from all relevant international, national and institutional ethics committees. Written informed consent is provided by the caretaker of all participants. Results will be shared with local and national stakeholders, and disseminated via peer-reviewed open-access journals and scientific meetings. TRIAL REGISTRATION NUMBER: NCT04285021. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.Entities:
Keywords: infectious diseases; paediatrics; primary care; public health
Year: 2021 PMID: 33495264 PMCID: PMC7839891 DOI: 10.1136/bmjopen-2020-045826
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692